deltatrials
Completed PHASE2 NCT00063401

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Sponsor: Bristol-Myers Squibb

Conditions Fallopian Tube Neoplasms Ovarian Cancer Peritoneal Neoplasms
Interventions Carboplatin Cetuximab: Paclitaxel
Updated 7 times since 2017 Last updated: Apr 7, 2010 Started: Sep 30, 2003 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

Listed as NCT00063401, this PHASE2 trial focuses on Fallopian Tube Neoplasms and Ovarian Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Nov 2019 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States
  • • Philadelphia, United States